Pleural Fluid Mesothelin as an Adjunct to the Diagnosis of Pleural Malignant Mesothelioma
Table 1
Final diagnosis, patient characteristics, and mesothelin results.
Final diagnosis
Female, (%)
Age, mean (range)
Mesothelin1,2 nM
Mesothelin positive3 (%)
MM
183
26 (14%)
71 (45–97)
28 ± 4.3
122 (67%)
Non-MM malignancy all
436
226 (52%)
70 (24–97)
4.7 ± 3.9***
50 (11%)
Lung cancer
182
78 (43%)
72 (36–97)
5.2 ± 3.6
26 (14%)
Breast cancer
62
61 (98%)
66 (37–96)
4.1 ± 3.3
3 (5%)
Ovarian cancer
11
11 (100%)
64 (42–77)
19 ± 5.1
5 (45%)
Pancreatic cancer
10
2 (20%)
68 (56–77)
6.3 ± 8.4
3 (30%)
Other malignancies
171
74 (44%)
68 (24–94)
3.9 ± 4
13 (8%)
Nonmalignant all
712
260 (37%)
69 (18–99)
3.2 ± 3***
3 (0.4%)
Transudate
141
58 (41%)
74 (34–99)
3.4 ± 2.7
0 (0%)
Exudate
129
44 (34%)
67 (19–94)
3.4 ± 3.5
2 (2%)
Infection
165
58 (35%)
65 (29–96)
2.3 ± 3.8
1 (0.6%)
Benign—not specified
277
106 (38%)
70 (18–96)
3.5 ± 3.1
0 (0%)
expontiated mean of log transformed data plus/minus standard error of log transformed data * 100, in the most recent sample received per patient.
2significant difference between indicated cohorts and the mesothelioma cohort as a whole () as determined by Student’s -test (***is ).
3Number of individuals in whom soluble mesothelin was >20 nM in the most recent sample received per patient.
